PharmaGraphX

Log in Get Started

Linagliptin

Tradjenta, Jentadueto, Glyxambi, Trijardy

Uncategorized

Standard

Half-life

12 hours (effective); ~100 hours (terminal)

Protein Binding

70-80%

Metabolized By

N/A

External

Drugs.com

Mechanism of action

Inhibits DPP-4, prolonging incretin activity

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Type 2 Diabetes Mellitus
·Type 2 Diabetes Mellitus (T2DM)
·Diabetes Mellitus Type 2
·Mild Cognitive Impairment
·Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Interactions

No curated interaction pairs are recorded for Linagliptin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nasopharyngitis
Hypoglycemia (with SU)
Cough

Food, alcohol & herbal

Alcohol · moderate

May increase hypoglycemia risk

Pharmacokinetics

Half-life: 12 hours (effective); ~100 hours (terminal)
Protein binding: 70-80%

Pregnancy & lactation

Not recorded for Linagliptin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement